Fracture Risk Bumped With Testosterone Therapy in Hypogonadal Men
Testosterone treatment didn’t offer protection against fractures in men with hypogonadism, a TRAVERSE subtrial indicated. Compared with placebo, men who were on a testosterone gel actually had a significantly higher risk for fracture (HR 1.43, 95% CI 1.04-1.97), found Peter Snyder, MD, of the University of Pennsylvania in Philadelphia, and colleagues. During the median 3.19-year […]
Testosterone for Hypogonadism Cleared So Far of Prostate Cancer Risk
Men treated with testosterone replacement therapy (TRT) for hypogonadism didn’t have an increase in adverse prostate events, the TRAVERSE trial found. Over a mean follow-up of 33 months, those who used topical 1.62% testosterone gel had a 0.19% incidence of high-grade prostate cancer (Gleason score ≥4 + 3), similar to the 0.12% among placebo-treated men […]
No Early Cardiovascular Risks With Testosterone Treatment
Testosterone treatment for hypogonadism did not increase short- or medium-term risks for cardiovascular events, according to a systematic review and meta-analysis. Cardiovascular risks were similar between men in the testosterone group and those in the placebo group (7.5% vs 7.2%; OR 1.07, 95% CI 0.81-1.42, P=0.62), reported Channa Jayasena, PhD, of Imperial College London, at […]
Another Oral Testosterone Undecanoate OK’d for Hypogonadism
The FDA has approved a new oral testosterone undecanoate capsule (Tlando) for hypogonadism, Antares Pharma announced. This androgen is indicated for testosterone replacement therapy in adult men for conditions associated with a deficiency or absence of endogenous testosterone, including congenital or acquired primary hypogonadism, as well as congenital or acquired hypogonadotropic hypogonadism. “The FDA approval […]